R ecent success in identifying genes involved in complex diseases such as coronary artery disease (CAD) and myocardial infarction (MI) has been largely brought about by 2 major developments. First, modern array technology now enables simultaneous measurement of hundreds of thousands of single nucleotide polymorphisms (SNPs) across the human genome. Second, collaborations have been formed, bringing together large collections of well-phenotyped individuals. With respect to CAD and MI, this effort was established by highly informative collections of patients with premature disease. Up to the present, these studies have individually identified at least 13 chromosomal loci with genome-wide significance for association with MI and other forms of CAD. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] nature of atherosclerosis, with multiple genetic factors contributing only small effects to disease manifestation. In fact, for a typical genome-wide association study (GWAS) with Ϸ1000 cases and controls, the power to detect any effects at stringent significance levels is low. 11 To increase the power, we formed a consortium to pool data across all published and multiple unpublished GWAS for CAD and MI. Here, we aim to provide a detailed description of the structure and functioning of our consortium.
Methods

General Organization of the Consortium
Our consortium-the Coronary ARtery DIsease Genome-wide Replication And Meta-analysis (CARDIoGRAM) consortium-is based on a core of previously successful collaborations among single participating studies. 4 -8 These case-control or prospective cohort studies both have detailed phenotyping for CAD, MI, or both as previously described. 8 Control subjects have been derived from population-based studies in most investigations. For all of the participating studies, genome-wide scans were performed in the years 2006 to 2009. Statistical methods have been standardized across the studies, and an analysis platform has been created to allow summarized analyses on CAD, MI, and related phenotypes.
The organizational structure comprises a steering committee of either the principal or another key investigator of the participating studies and representatives from the statistical groups. The analysis team comprises 1 responsible genetic epidemiologist or statistical geneticist from each study. Standard operating procedures were generated to harmonize the data analyses. A centralized database for aggregated data is provided by the Cardiogenics consortium (http://www.cardiogenics.eu/web/) to allow centralized and decentralized access and analysis by all of the statistical groups ( Figure 1 ). Transparency, with disclosure of any other collaborations with the potential to create conflict (including follow-up experiments), has been encouraged in order to sustain a high level of trust within the consortium. A consensus has been established by the steering committee to discourage intellectual property claims on aggregate findings before publication of results.
Statistical Analysis Methods
Different genotyping platforms have been used across the studies. An analysis restricted only to SNPs genotyped on all platforms would have been severely limited. For instance, the estimated overlap between the Affymetrix Genome Wide Human SNP Array 6.0 and the Illumina Human-1 mol/L chip is only about 250 000 SNPs. To allow for combined analyses across different platforms, missing SNPs were imputed by each study.
To summarize the evidence across studies, we used aggregated data from association analyses for CAD and MI as well as for important subgroups as outlined a priori in the study protocol. The planned statistical analysis across all studies ending in the meta-analysis has 6 steps, as summarized in Table 1 . In brief, after quality control, SNP-wise association tests are computed using log-additive genetic models with adjustment for age and sex in every study. After upload Analyses are performed in every study separately by the statistical group and then submitted to the central database. The analysis group checks the data quality within each study and queries individual studies on summary data. Once the initial quality control has been performed and data summaries are consistent across individual studies, these qualitycontrolled data are updated in the database and used for meta-analysis.
of the summary data and centralized quality control, a meta-analysis across all studies is performed for every SNP separately. Here, depending on the heterogeneity between studies, fixed (inverse variance weighting) or random effects (DerSimonian-Laird) models are calculated, and outlying studies excluded.
As a proof-of-principle analysis, a number of SNPs in the 9p21 region with known association to CAD and MI were analyzed upfront. Specifically, we selected 3 SNPs that were reported as lead SNPs in the first publications by McPherson et al 2 (rs2383206), Helgadottir et al 3 (rs10757278), and Samani et al 4 (rs1333049). In addition, we chose the SNP rs10811661 in the same chromosomal region that was associated with type 2 diabetes but not with CAD. 12, 13 Given the potential etiologic heterogeneity of CAD, we predefined several subgroup analyses. Specifically, we chose to compare association results between female and male sex (female cases with female controls versus male cases with male controls) and younger onset and older onset cases (older cases with all controls versus younger cases with all controls). In addition, we analyzed age at first MI as a phenotype in cases only. We illustrate the results of these predefined subgroup analyses for the SNP rs1333049 with a known association to CAD and MI.
Replication Strategy and Levels of Evidence
In addition to providing a powerful meta-analysis, CARDIoGRAM has integrated a replication stage into the analysis plan, assembling a substantial resource of more than 60 000 samples, which are available for wet-laboratory or in silico replication. Replication has been predefined as being successful if the 1-sided P value remains Ͻ0.05 after correction for the testing of the number of genetic loci taken forward.
Because of the size of the primary CARDIoGRAM meta-analysis combined with the replication sample size, it is unlikely that a similarscale experiment will be performed in the near future to independently verify the findings that emerge from our study. Mindful of this and to account for the caveats involved in combining data sets for metaanalysis, the CARDIoGRAM consortium has decided a priori to categorize the principal findings into different levels of evidence that depend on the strength of the association observed in the meta-analysis and replication samples. Establishing such criteria in advance avoids bias, helps with interpretation of findings, and may help to guide future work. The criteria we used are as follows:
• Level 1: Regions with SNPs that display (1) genome-wide significance with PϽ5ϫ10 Ϫ8 in a joint analysis of the GWAS and wet-laboratory replication stages and (2) display independently significant association in the replication stage at a threshold of 0.05 divided by the number of loci tested in replication. • Level 2: SNPs that display genome-wide significance with PϽ5ϫ10 Ϫ8 in a joint analysis of the GWAS and wet-laboratory replication stages but do not display independent significant association in the replication stage. • Level 3: SNPs with levels of association evidence with PϾ5ϫ10 Ϫ8 but Ͻ10 Ϫ6 in a joint analysis of the GWAS and wet-laboratory replication stages.
These criteria will be applied to the main comparison and to all of the subgroup analyses.
Results
A description of the participants in each study is given in Table 2 . Online-only Data Supplement Table 1 summarizes the genotyping platforms and imputation methods used for the individual studies.
Collectively, our consortium provides Ͼ10 times the number of cases and controls than the largest published individual CAD GWAS. Consequently, our meta-analysis will have increased power to detect small genetic effects. For instance, the power is Ͼ80% to detect an odds ratio (OR) of only 1.1 at the level of genome-wide significance, provided that the mean minor allele frequency (MAF) is at least 15% (see Figure 2 ). For the replication stage, the estimated power is shown in Figure 3 .
The results for our proof-of-principle analysis are shown in Table 3 and Figure 4 . In agreement with prior studies, the results show a strong association between the SNPs rs1333049, Table 1 
. Algorithm Applied for Analysis
Step Description 1. Perform analyses in every study separately.
According to an a priori standard operating procedure, analyses are performed in every study separately. Here, quality-control indicators and tests for association with CAD are computed. Specifically, a log-additive model frequency test that takes into account the uncertainty of possibly imputed genotypes is performed with adjustment for age (at first CAD/MI onset for cases or recruitment for controls) and sex.
2. Upload to a central database.
The full set of summary data, including aggregated genotypes, quality-control parameters, and results from the association analyses are uploaded to a central database.
3. Perform quality control of data.
Quality control of the data is performed centrally according to previously agreed criteria, including a check of consistency of the given alleles across all studies, quality of the imputation, deviation from Hardy-Weinberg equilibrium in the controls, the MAF, and the call rate. In every study, the variance inflation factor is computed from genotyped SNPs and used for adjustment.
4.
Apply meta-analysis procedure.
Separately for every SNP from every study that passes the quality criteria, the following procedure is applied for the meta-analysis:
(1) Fixed effects models are calculated together with Q-and I statistics for testing homogeneity. If there is no heterogeneity (PϾ0.01 for Q), fixed effects models are reported.
(2) If there is evidence for heterogeneity (PϽ0.01 for Q), an outlier test is performed comparing each study with the average of the others.
(a) If outliers are found with PϽ0.01/(number of studies providing data for the SNP), the most extreme study is excluded, and the procedure is repeated from step (1).
(b) If no outliers are found but heterogeneity was apparent, random effects models are calculated.
5.
Compute the overall on the results of the meta-analysis.
Finally, in addition to the adjustment for each individual study inflation factor , the overall is computed on the results of the meta-analysis. Primary statistical evidence is based on individual study adjustment, but results with an additional adjustment for the overall based on the meta-analysis also are reported.
6. Conduct the main analyses in at least 2 sites.
To ensure high quality of the statistical analysis, the main analyses are conducted in at least 2 sites in parallel and independently. Importantly, all sites have access to all data sets to provide additional quality checks of the principal findings.
rs2383206, and rs10757278 and CAD but no evidence for association for rs10811661. The SNP rs1333049 was also part of the previous meta-analysis by Schunkert et al. 19 In that report, the overall OR was 1.29 with a 95% CI of 1.22 to 1.37, virtually identical to our current result.
Results for the subgroup analyses of rs1333049 are shown in Figure 5 . Except for the analysis of older cases, results are more homogenous across study groups so that fixed effects models are selected. Overall, the association effect is strongest among younger cases. Moreover, there was an association of the Age and BMI data are presented as mean (SD). AMI indicates acute myocardial infarction; BMI, body mass index; CABG, coronary artery bypass graft; CHD, coronary heart disease; CVA, cerebrovascular accident; CVD, cardiovascular disease; MONICA, Multinational MONItoring of trends and determinants in CArdiovascular disease; NSTEMI, non-ST-segment elevated myocardial infarction; PTCA, percutaneous transluminal coronary angioplasty; STEMI, ST-segment elevation myocardial infarction; PAD, peripheral arterial disease; PCI, percutaneous coronary intervention.
*Information on BMI in the deCODE study is available for 81.7% of the cases and 66.8% of the controls. †For cases, age at diagnosis; for controls, age at recruitment. ‡Cases, angiographic CAD (Ͼ50% stenosis in at least 1 vessel); controls, angiography normal or Ͻ10% stenosis in all vessels. ʈWTCCC controls comprise an equal number of subjects from the 1958 Birth Cohort and from the National Blood Service Donors. The latter were recruited in equal 10-year age bands from age 11 to 70 years. Additional phenotypes are not available for these controls.
number of the risk-conferring alleles with earlier age of first MI (␤ ϭ0.37; SEϭ0.12; Pϭ0.0015).
Discussion
The GWAS approach has proven useful in the identification of genetic variants affecting the risk of complex diseases. Specifically, several GWAS investigations have identified genes that reproducibly demonstrate association with CAD and MI. [5] [6] 8 Given that up to 2.5 million comparisons are carried out in parallel, a limitation of the approach is the clear discrimination between true and false associations. Consequently, stringent thresholds for genotyping quality and statistical significance need to be passed for reliable demonstration of a true-positive association. Large sample sizes are required to detect modest, but biologically important associations, and replication studies are required to minimize any remaining doubt about the reproducibility and relevance of such findings.
Almost all variants that have so far been associated with CAD or MI demonstrate risk ratios between 1.1 and 1.3 per risk allele. Given the small effect sizes, only 1 or few novel chromosomal loci were identified by each of the published studies. The newly formed CARDIoGRAM consortium will enhance the statistical power to detect true association by increasing the sample size by a factor of 10 for cases and 20 for controls. Indeed, all of the predefined subgroups are larger than the sample sizes of currently published GWAS. These larger samples are likely to substantially enhance the detection of true associations for CAD risk. Furthermore, we have prepared for a substantial replication phase and defined hierarchical levels of evidence a priori to help attach an appropriate level of confidence to our various findings as they emerge.
An unresolved problem in the interpretation of an individual GWAS is the potential for heterogeneity of risk allele effects across different individual populations. To meet this challenge, CARDIoGRAM has prespecified methods to uncover outliers and potential false-positive associations. Compared with disease states with intermediate or quantitative phenotypes, we anticipate generally higher levels of heterogeneity in the clinical definition of CAD and MI as a result of greater variation in clinical expression (eg, MI versus angiographic CAD) and in ascertainment (eg, cutoff for age at onset at young age in some clinical samples versus predominantly advanced age of onset in population-based samples). Relevant, but to a lesser degree, may be local or population-based differences in the genomic structure. We believe that the sample size of CARDIoGRAM will allow us to address this heterogeneity by performing stratified analyses that investigate clinically important questions, including age of onset of disease and sex.
The CARDIoGRAM consortium wishes to facilitate the in silico replication of findings from other investigators, with independent samples studying either candidate genes or genome-wide data. The consortium is limited in its ability to provide insights into the genetic risk of CAD in nonwhite populations. However, CARDIoGRAM will provide a substan-tial number of validated loci in white individuals that can be tested for association in nonwhite populations. Reciprocally, we will offer a large white race study sample for testing the relevance of novel loci discovered in GWAS of nonwhite populations. It will be of particular interest, therefore, to com- Figure 5 . Results for subgroup association analysis for SNP rs1333049. Shown are ORs with 95% CIs comparing female cases versus female controls, male cases versus male controls, old cases (Ն50 years) versus all controls, and young cases (Ͻ50 years) versus all controls. Numbers below the x axis denote P values, fixed effects (FE) or random effects (RE) models, and number of cases/controls. . Heterogeneity between the studies is indicated by I 2 , and for every study, it is indicated whether the respective SNP was genotyped (G) or imputed (I) or a mixture of genotyped and imputed (NA).
pare our findings for individuals of European ancestry with those observations made for other studies recruiting members of other racial/ethnic groups. A secondary benefit that we foresee for the future use of the CARDIoGRAM data set and for further study of the results of planned meta-analyses will be to explore and strengthen evidence for the existence of a causal association of MI, CAD, or both with biomarkers and other intermediate traits. Many of these biomarkers and traits are known to have robust associations with CAD (eg, C-reactive protein, high-density lipoprotein cholesterol, hyperhomocysteinemia), and the list is continually expanding. Determining whether these associations are causal (ie, the biomarker or trait is involved in the pathogenesis of CAD) versus a consequence of reverse causality (ie, the biomarker is raised or decreased by the presence of CAD) versus a result of pleiotropic, but independent effects of another factor on both the marker and the CAD risk is an important clinical question with particular relevance for identifying therapeutic targets. 20 If variants causally affect the level of biomarker or trait, then one can immediately investigate whether those variants also affect CAD risk to a degree that is comparable to the quantitative association of the biomarker or trait with CAD risk. 20 Because the effect of the variant on the trait may be modest, the impact on CAD risk is likely to be small, and large sample sizes are required to demonstrate or refute an association of the variant with CAD risk. In this regard, we expect CARDIoGRAM to make a significant contribution.
In summary, we describe the design, structure, and plans of a large consortium formed to investigate the genetic basis of CAD and MI using genome-wide association data. Further, we discuss the likely benefits of the resource that will be created for the cardiovascular genetics community.
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